Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: Lin Shen
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Jinjun Liu, MD
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309· Phase 1· Antengene Biologics Limited· Source
Contact: Changhao Xie
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Rui Wang
Not yet recruiting
Effects of Esmolol on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock
NCT07657754· First Affiliated Hospital of Wannan Medical College· Source
Contact: Cheng Liu
Not yet recruiting
Papaverine and Sublingual Microcirculation in Septic Shock
NCT07657741· First Affiliated Hospital of Wannan Medical College· Source
Contact: Cheng Liu, PhD
Not yet recruiting
Effects of Dexmedetomidine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock
NCT07657715· First Affiliated Hospital of Wannan Medical College· Source
Contact: Cheng Liu, PhD
Not yet recruiting
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source
Contact: zhengyu song
Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT07602504· Anhui Provincial Hospital· Source
Contact: Zheng Lu
Not yet recruiting
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Jiajia Li, Doctor
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Contact: Yinping Zhong
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· Phase 2· Eisai Co., Ltd.· Source
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Contact: Yongjun Mei
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Hao Jiang
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: lei liu
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· Phase 1· Shanghai Henlius Biotech· Source
Contact: Henlius
Active, not recruiting
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667· Affiliated Hospital of Nantong University· Source
Contact: Yajun Li Director of the Nursing, MS
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275· Phase 2/3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Chuanmiao Liu
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source
Contact: Zhang Mingliang
Recruiting
China Liver Cancer Clinical Registry Cohort Database (HEAL)
NCT06777485· Anhui Provincial Hospital· Source
Contact: Zheng Lu
Not yet recruiting
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461· Phase 3· InnoBM Pharmaceuticals Co., Ltd.· Source
Contact: Chuntao G PM
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Not yet recruiting
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source
Contact: Xiaolei Hu, Doctor
Enrolling by invitation
Health Behavior Management Program for Patients With Coronary Heart Disease
NCT07330882· The First Affiliated Hospital of Bengbu Medical University· Source
Active, not recruiting
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
NCT06434610· Phase 2· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source
Contact: Hongli Liu
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994· Phase 3· InnoCare Pharma Inc.· Source
Contact: Yanli Yang
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
NCT06406205· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source
Contact: Yongjun Mei
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Jinhai Zhu
Recruiting
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT05905172· Phase 3· Beijing Continent Pharmaceutical Co, Ltd.· Source
Contact: Wei Li
Active, not recruiting
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287· Phase 3· RemeGen Co., Ltd.· Source
Active, not recruiting
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894· Phase 3· Taizhou Hanzhong biomedical co. LTD· Source
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731· Phase 1/2· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432· Phase 1/2· Betta Pharmaceuticals Co., Ltd.· Source
Contact: Wanlin Chen, Master
Active, not recruiting
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499· Phase 1/2· Klus Pharma Inc.· Source